Prognostic and Predictive Effects of Tumor and Plasma miR-200c-3p in Locally Advanced and Metastatic Breast Cancer

• Published in: Cancers Vol. 14; no. 10; p. 2390
• Main Authors: Navarro-Manzano, Esther, Luengo-Gil, Ginés, González-Conejero, Rocío, García-Garre, Elisa, García-Martínez, Elena, García-Torralba, Esmeralda, Chaves-Benito, Asunción, Vicente, Vicente, Ayala de la Peña, Francisco
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 12-05-2022; MDPI
• Subjects: Biobanks; Biomarkers; Breast cancer; Cancer therapies; Chemotherapy; Clinical medicine; Gene expression; Medical diagnosis; Medical prognosis; Medical research; Metastases; Metastasis; MicroRNAs; Patients; Plasma; Plasma levels; Scintigraphy; Tomography; Tumors; Womens health; neoadjuvant chemotherapy; breast cancer; plasma biomarkers; prognostic factor; miR-200c; predictive factor
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers14102390

While the role of miR-200c in cancer progression has been established, its expression and prognostic role in breast cancer is not completely understood. The predictive role of miR-200c in response to chemotherapy has also been suggested by some studies, but only limited clinical evidence is available. The purpose of this study was to investigate miR-200c-3p in the plasma and primary tumor of BC patients. The study design included two cohorts involving women with locally advanced (LABC) and metastatic breast cancer. Tumor and plasma samples were obtained before and after treatment. We found that miR-200c-3p was significantly higher in the plasma of BC patients compared with the controls. No correlation of age with plasma miR-200c-3p was found for controls or for BC patients. MiR-200c-3p tumor expression was also associated with poor overall survival in LABC patients treated with neoadjuvant chemotherapy, independently of pathological complete response or clinical stage. Our findings suggest that plasmatic miR-200c-3p levels could be useful for BC staging, while the tumor expression of miR-200c-3p might provide further prognostic information beyond residual disease in BC treated with neoadjuvant chemotherapy.